SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

RNV ReNerve Limited

Healthcare · Biotechnology · website
$0.08
52wk 0.07 – 0.22
Overall
55.9
Value
58.1
Growth
100.0
Health
69.2
Quality
0.0
Momentum
32.1
Dividend
—
Price
About ReNerve Limited

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; and amniotic tissue product ranges used to aid the healing of wounds under the Empliq brand. In addition, it provides Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand that are in development phase. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

Price analytics

Returns

1 day 5.0%
1 week 13.5%
1 month 9.1%
3 months 6.3%
6 months -16.0%
1 year -40.0%
3 years —

Risk

Volatility (1y ann.) 98.5%
Beta vs ASX 200 -0.01
Sharpe (1y) -0.13
VaR 95% (1-day) -6.8%
Max drawdown (1y) -61.1%
Off 1-year high -52.0%

Technicals

RSI(14) 75 OB
vs 50DMA 10.0%
vs 200DMA -7.6%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 58.1
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
46
Price / Sales
0
Growth 100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 32.1
6-month return vs ASX 200
7
Price vs 200-day average
25
Price vs 50-day average
100
Position in 52-week range
10

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$14.56M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.04
Dividend yield
—
Payout ratio
0.0%
Beta
—
EV / EBITDA
-2.03
Price / Book
4.67
ROE
-133.1%
Operating margin
-1,007.0%
Net margin
0.0%
Total cash
$1.49M
Total debt
$201,554
Current ratio
3.13
Debt / Equity
0.06
Free cash flow
$-4.66M
Avg volume
47,988
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$510.36K
  • Gross profit$271.32K
  • Operating income-$6.52M
  • Net income-$5.57M
  • Diluted EPS—
  • Free cash flow-$5.95M
  • Net debt-$1.29M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4